Kalshi and Polymarket bets on clinical trials criticized as 'ghastly'
Researchers warn betting on clinical trials could incentivize insider trading and interfere with drug development. But Kalshi and Polymarket say they provide valuable information to patients.
This is a summary aggregated from NPR News. Read the complete article on the original site:
Read full article at NPR News
